NSAIDs-enteropathy — prevention and treatment aspects

E.N. Kareva^1,2

¹Sechenov First Moscow State Medical University

²Pirogov Russian National Research Medical University, Moscow

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used medicines worldwide, and their side effects number
is very large. In the first instance — NSAIDs-gastropathy, although, the NSAIDs use causes damage to the small intestine (NSAIDs-enteropathy) on the long-term basis in 50–70% of patients. This condition is characterized by the presence of the fecal blood, anemia of unknown etiology, abdominal symptoms, and phenomena of intestinal obstruction. Sometimes NSAIDs-enteropathy has serious consequences. NSAIDs cancellation is not always possible (for example, in chronic pain syndrome) and does not always lead to the NSAIDs-enteropathy cure. To date, not a single medicine with proven effectiveness to prevent this side effect has been proposed. Apparently, this is not fully explained by the mechanism of NSAIDs-enteropathy pathogenesis. The most promising  hypothesis is the participation of individual microflora representatives in the enteropathy development, so the intestinal flora modulation with probiotics can become a basic therapeutic strategy for the prevention and treatment of such damage. Role evaluation of lacto-and bifidobacteria individual strains in the NSAIDs-enteropathy development requires focused attention. Prospective randomized clinical trials conduction will assess probiotics effectiveness in the treatment and prevention of NSAIDs-enteropathy.

Keywords: NSAIDs-enteropathy, mechanisms of pathogenesis, microbiota, probiotics, Maxilac.

For citation: Kareva E.N. NSAIDs-enteropathy — prevention and treatment aspects. RMJ. 2019;7:11–14.